A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer.

被引：29
|
作者：
Finn, Richard S.
Javle, Milind M.
Tan, Benjamin R.
Weekes, Colin D.
Bendell, Johanna C.
Patnaik, Amita
Khan, Gazala Naaz
Laheru, Dan
Anderson, Lisa
Christy-Bittel, Janna Lynn
Barrett, Emma
Guthrie, Kari
Litwiler, Kevin S.
Bekaii-Saab, Tanios S.
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Washington Univ, Sch Med, St Louis, MO 63110 USA
[4] Univ Colorado, Canc Ctr, Aurora, CO USA
[5] Sarah Cannon Res Inst, Nashville, TN USA
[6] South Texas Accelerated Res Therapeut START, Ctr Canc Care, San Antonio, TX USA
[7] Univ Michigan Hosp, Ann Arbor, MI USA
[8] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[9] Array BioPharma, Boulder, CO USA
[10] Ohio State Univ, Med Ctr, Columbus, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.220
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
220
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase Ib study of binimetinib (MEK162) in combination with capecitabine in gemcitabine-pretreated advanced biliary tract cancer.
    Kim, Jin Won
    Lee, Kyung-Hun
    Kim, Ji-Won
    Suh, Koung Jin
    Bang, Ju-Hee
    Bang, Yung-Jue
    Oh, Do-Youn
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer.
    Cho, May Thet
    Lim, Dean
    Synold, Timothy W.
    Frankel, Paul Henry
    Leong, Lucille A.
    Chao, Joseph
    Chung, Vincent M.
    Chen, Yuan
    Sentovich, Stephen
    Luevanos, Eloise
    Fakih, Marwan
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer.
    Cho, May Thet
    Lim, Dean
    Synold, Timothy W.
    Frankel, Paul Henry
    Leong, Lucille A.
    Chao, Joseph
    Chung, Vincent M.
    Chen, Yuan
    Sentovich, Stephen
    Luevanos, Eloise
    Fakih, Marwan
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [4] Results of a phase 1 study of MEK162, an oral MEK inhibitor, in Japanese patients with advanced solid tumors
    Shimokata, T.
    Watanabe, K.
    Shibata, T.
    Inada-Inoue, M.
    Shirao, K.
    Hirashima, Y.
    Fukuhara, S.
    Tokushige, K.
    Zubel, A.
    Ando, Y.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S870 - S871
  • [5] ARRY-438162, a selective, potent inhibitor of MEK1/2 in clinical development for the treatment of inflammatory disease
    Koch, Kevin
    INFLAMMATION RESEARCH, 2006, 55 : S98 - S98
  • [6] MEK Inhibitor Binimetinib (MEK162) in Relapse and Refractory Acute Myeloid Leukemia: Results of a Phase I/II Study
    Maiti, Abhishek
    Naqvi, Kiran
    Kadia, Tapan
    Borthakur, Gautam
    Takahashi, Koichi
    Bose, Prithviraj
    Daver, Naval
    Patel, Ami
    Alvarado, Yesid
    Ohanian, Maro
    DiNardo, Courtney
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    Ravandi, Farhad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S199 - S199
  • [7] A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors
    Watanabe, K.
    Otsu, S.
    Hirashima, Y.
    Morinaga, R.
    Nishikawa, K.
    Hisamatsu, Y.
    Shimokata, T.
    Inada-Inoue, M.
    Shibata, T.
    Takeuchi, H.
    Watanabe, T.
    Tokushige, K.
    Maacke, H.
    Shiaro, K.
    Ando, Y.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (06) : 1157 - 1164
  • [8] MEK162 (ARRY-162), a novel MEK 1/2 inhibitor, inhibits tumor growth regardless of KRas/Raf pathway mutations
    Winski, S.
    Anderson, D.
    Bouhana, K.
    Impastato, R.
    Woessner, R.
    Zuzack, J.
    Tunquist, B.
    Garrus, J.
    Pheneger, T.
    Lee, P.
    EJC SUPPLEMENTS, 2010, 8 (07): : 56 - 56
  • [9] A Phase I/Ib Study of Binimetinib (MEK162), a MEK Inhibitor Plus Carboplatin/Pemetrexed in Non-Squamous NSCLC
    Graham, D.
    Chen, E.
    Pisters, K.
    Bradbury, P.
    Trinkaus, M.
    Chan, M.
    Arif, S.
    Zurawska, U.
    Rothenstein, J.
    Zawisza, D.
    Effendie, S.
    Sawczak, M.
    Leighl, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S481 - S482
  • [10] A Phase I/Ib study of MEK162 (binimetinib), a MEK inhibitor, in combination with carboplatin and pemetrexed in patients with non-squamous NSCLC.
    Karim, Safiya
    Feld, Ronald
    Leighl, Natasha B.
    Shepherd, Frances A.
    Bradbury, Penelope Ann
    Liu, Geoffrey
    Graham, Donna M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345